START (Strategic Timing of Antiretroviral Therapy) is a randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until CD4+ declines below 350 cells/mm3 in terms of morbidity and mortality in HIV-1 infected persons who are antiretroviral naïve with a CD4+ count above 500 cells/mm3.

Participants will be randomized 1:1.

For more information, contact Vicky Pena at 919-668-0166 or violeta.pena@duke.edu.